Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Jul 08, 2021

SELL
$5.19 - $6.73 $9,912 - $12,854
-1,910 Reduced 81.28%
440 $2,000
Q4 2020

May 19, 2021

BUY
$5.3 - $6.71 $10,467 - $13,252
1,975 Added 526.67%
2,350 $2,000
Q2 2020

Sep 07, 2021

BUY
$4.35 - $8.08 $1,631 - $3,030
375 New
375 $2,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.18B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Geneos Wealth Management Inc. Portfolio

Follow Geneos Wealth Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Geneos Wealth Management Inc. with notifications on news.